HK Stock Market Move | TRANSTHERA-B (02617) surged over 13% to a new high, nearly 1.8 times its IPO price. Its core product has received FDA fast-track approval.

TRANSTHERA-B (02617) rose more than 13% in the afternoon, hitting a new high of 36.35 Hong Kong dollars, up nearly 180% from the IPO price of 13.15 Hong Kong dollars. As of the time of publication, it has risen by 12.34%, reaching 35.95 Hong Kong dollars, with a turnover of 16.9288 million Hong Kong dollars. In terms of news, Pharmaron Health announced earlier this month that its independently developed multi-target kinase inhibitor, Terengertinib (TT-00420), has been granted fast track certification by the US Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that Terengertinib is currently a multi-target kinase inhibitor in phase III clinical trials worldwide, targeting FGFR/VEGFR, JAK, and Aurora kinases to show anti-tumor effects. Clinical trials in the US and China have shown its potential efficacy in the treatment of various solid tumors. EB SECURITIES International previously released research reports stating that the market penetration rate of innovative therapies (including FGFR inhibitors) is expected to increase, and the compound annual growth rate of the market size of CCA is expected to be higher than the incidence rate. Guoyuan International also stated that the company is a leader in R&D in the industry, and Terengertinib is the world's first and only FGFR inhibitor to enter registered clinical trials for the treatment of patients with recurrent or refractory bile duct cancer. It is also the world's first research drug with clinical efficacy evidence that may simultaneously inhibit the FGFR/JAK pathway and target metastatic castration-resistant prostate cancer.